Abstract
Recognition of asthma as a heterogeneous disease revealed different potential molecular targets and urged the development of targeted, customized treatment modalities. Evidence was provided for different inflammatory subsets of asthma and more recently, further refined to T helper (Th)2-high and Th2-low subphenotypes with different responsiveness to standard and targeted pharmacotherapy. Given these differences in immunology and pathophysiology, proof of concept studies of novel treatment modalities for asthma should be performed in adequate, well-defined phenotypes. In this review, we describe both existing and novel biomarkers of Th2-inflammation in asthma that can be applied to classify asthma subphenotypes in clinical studies and for treatment monitoring.
| Original language | English |
|---|---|
| Pages (from-to) | 477-486 |
| Number of pages | 10 |
| Journal | Current Allergy and Asthma Reports |
| Volume | 13 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - Oct-2013 |
Keywords
- Asthma
- Phenotype
- Th2 inflammation
- Biomarkers
- Eosinophils
- Periostin
- TARC
- Eotaxin
- Feno
- IL-4
- IL-5
- IL-13
- Sputum
- BAL
- EOSINOPHIL CATIONIC PROTEIN
- ACTIVATION-REGULATED CHEMOKINE
- BRONCHOALVEOLAR LAVAGE FLUID
- OBSTRUCTIVE PULMONARY-DISEASE
- RANDOMIZED CONTROLLED-TRIAL
- BRONCHIAL EPITHELIAL-CELLS
- ASPIRIN-INTOLERANT ASTHMA
- EXHALED BREATH CONDENSATE
- NITRIC-OXIDE SYNTHASE
- LATE-PHASE REACTIONS